Comparison of Gliclazide Treatment with Diet Therapy on Acute Phase Protein Levels in Patients with Type 2 Diabetes

Basit Öğe Kaydı
dc.contributor.authorMemişoğulları, Ramazan
dc.contributor.authorAkçay, Fatih
dc.contributor.authorCoşkun, Abdurrahman
dc.contributor.authorKorkmaz, Uğur
dc.date.accessioned2020-04-30T22:41:19Z
dc.date.available2020-04-30T22:41:19Z
dc.date.issued2009
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionCoskun, Abdurrahman/0000-0002-1273-0604en_US
dc.descriptionWOS: 000264805800012en_US
dc.description.abstractAims: It is known that there is a relationship between diabetic complications and chronic inflammation characterized by alterations in circulating acute phase proteins. It has been emphasized that inflammation contributes to diabetic complications and that gliclazide -an antidiabetic sulfonylurea - decreases the development of such complications. In this study, we aimed to investigate whether gliclazide or diet treatment has an effect on serum levels of acute phase reactants. markers of inflammation. Materials and Methods: Fifty-six newly diagnosed patients with type 2 diabetes and 30 clinically healthy subjects were evaluated prospectively. Twenty-six patients were treated with proper diet and daily gliclazide (80 mg/daily) and 30 patients were randomized to only diet therapy for 6 months. After the 6-month therapy, blood was taken from patients and controls and acute phase protein levels were determined. Results: Serum alpha-1 acid glycoprotein. alpha-2 macroglobulin, alpha-1 antitrypsin. and albumin levels did not differ between the gliclazide and control groups. In the diet group. mean serum alpha-1 acid glycoprotein, alpha-2 macroglobulin, and alpha-1 antitrypsin were significantly higher and mean albumin level was significantly lower than the other groups. Glucose, hemoglobin A1C and haptoglobulin levels were significantly higher, whereas transferrin and prealbumin levels were significantly lower in both diet therapy and gliclazide therapy when compared with the control group. Mean C-reactive protein level did not differ between the groups. Conclusions: Levels of acute phase proteins significantly differ in type 2 diabetes when compared with healthy subjects. Gliclazide may provide better control on acute phase proteins.en_US
dc.identifier.endpage76en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage73en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3163
dc.identifier.volume39en_US
dc.identifier.wosWOS:000264805800012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetes mellitusen_US
dc.subjectinflammationen_US
dc.subjectgliclazideen_US
dc.subjectacute phase proteinsen_US
dc.titleComparison of Gliclazide Treatment with Diet Therapy on Acute Phase Protein Levels in Patients with Type 2 Diabetesen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3163.pdf
Boyut:
73.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu